Research programme: skin disorder therapeutics - Afecta Pharmaceuticals

Drug Profile

Research programme: skin disorder therapeutics - Afecta Pharmaceuticals

Alternative Names: AFX 210; AFX 2101; AFX 272; AFX 2721; AFX 372; AFX 3721

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Afecta Pharmaceuticals
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine CCL2 inhibitors; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Skin disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top